Patents by Inventor Haiyen E. Zhau

Haiyen E. Zhau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180185303
    Abstract: A mechanism of monoamine oxidases (MAOs) driven epithelium-to-mesenchymal transition (EMT) is disclosed. Also disclosed are methods for treating cancer by inhibiting or suppressing MAOs in cancer cells. Novel MAOs inhibitors, such as small molecules, siRNA, shRNA, antisense oligonucleotides, aptamers, decoys, and pharmaceutical compositions useful for treating cancer by disrupting the workings of MAOs are provided. In particular, a class of conjugates formed by covalently conjugating near infrared dye 783, IR-780, and MHI-148 to a MAO inhibitor, such as clorgyline, with and without encapsulation it in a nanoparticle is provided. Other aspects of the invention include methods for forming the nano-conjugates, method for monitoring treatment progress in a cancer patient by monitoring the changes in MAO activity, methods for screening patients who are at risk of cancer or differentiating different forms of cancer by assaying the level and location of MAO activity.
    Type: Application
    Filed: August 28, 2017
    Publication date: July 5, 2018
    Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Jean C. SHIH, Leland CHUNG, Haiyen E. ZHAU, Boyang Jason WU, Bogdan Z. OLENYUK
  • Publication number: 20170354747
    Abstract: This invention relates generally to cyanine-containing compounds; pharmaceutical compositions comprising cyanine-containing compounds; and methods of using cyanine-containing compounds for cancer cell imaging, cancer cell growth inhibition, and detecting cancer cells, for example. Compounds of the invention are preferentially taken up by cancer cells as compared to normal cells. This allows many uses in the cancer treatment, diagnosis, tracking and imaging fields.
    Type: Application
    Filed: February 2, 2017
    Publication date: December 14, 2017
    Inventors: Leland W.K. Chung, Lucjan Strekowski, Chunmeng Shi, Maged Henary, Gabor Patonay, James J. Krutak, Xiaojian Yang, Guodong Zhu, Ruoxiang Wang, Haiyen E. Zhau
  • Publication number: 20170314056
    Abstract: The present invention describes methods of identifying, detecting, imaging, isolating and locating cancer cells in a subject. The method involves the use of near-infrared (NIR) organic carbocyanine dyes, particularly, near infrared heptamethine cyanine dyes and the detection of the fluorescence of these NIR dyes. The uptake of these dyes by cancer cells and not by normal cells, as well as their high intensity, among other things, allow for the detection of cancerous cells in a subject and facilitate their subsequent isolation. Further, detection of many tumor types and tumor cell populations under cell culture and in vivo conditions are described.
    Type: Application
    Filed: April 13, 2017
    Publication date: November 2, 2017
    Inventors: Xiaojian Yang, Haiyen E. Zhau, Ruoxiang Wang, Leland W.K. Chung
  • Patent number: 9771625
    Abstract: A mechanism of monoamine oxidases (MAOs) driven epithelium-to-mesenchymal transition (EMT) is disclosed. Also disclosed are methods for treating cancer by inhibiting or suppressing MAOs in cancer cells. Novel MAOs inhibitors, such as small molecules, siRNA, shRNA, antisense oligonucleotides, aptamers, decoys, and pharmaceutical compositions useful for treating cancer by disrupting the workings of MAOs are provided. In particular, a class of conjugates formed by covalently conjugating near infrared dye 783, IR-780, and MHI-148 to a MAO inhibitor, such as clorgyline, with and without encapsulation it in a nanoparticle is provided. Other aspects of the invention include methods for forming the nano-conjugates, method for monitoring treatment progress in a cancer patient by monitoring the changes in MAO activity, methods for screening patients who are at risk of cancer or differentiating different forms of cancer by assaying the level and location of MAO activity.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: September 26, 2017
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Jean C. Shih, Leland Chung, Haiyen E. Zhau, Boyang Jason Wu, Bogdan Z. Olenyuk
  • Publication number: 20150335765
    Abstract: This invention relates generally to cyanine-containing compounds; pharmaceutical compositions comprising cyanine-containing compounds; and methods of using cyanine-containing compounds for cancer cell imaging, cancer cell growth inhibition, and detecting cancer cells, for example. Compounds of the invention are preferentially taken up by cancer cells as compared to normal cells. This allows many uses in the cancer treatment, diagnosis, tracking and imaging fields.
    Type: Application
    Filed: July 31, 2015
    Publication date: November 26, 2015
    Inventors: Leland W.K. Chung, Lucjan STREKOWSKI, Chunmeng SHI, Maged HENARY, Gabor PATONAY, James J. KRUTAK, Xiaojian YANG, Guodong ZHU, Ruoxiang WANG, Haiyen E. ZHAU
  • Publication number: 20150183736
    Abstract: This invention relates generally to cyanine-containing compounds; pharmaceutical compositions comprising cyanine-containing compounds; and methods of using cyanine-containing compounds for cancer cell imaging, cancer cell growth inhibition, and detecting cancer cells, for example. Compounds of the invention are preferentially taken up by cancer cells as compared to normal cells. This allows many uses in the cancer treatment, diagnosis, tracking and imaging fields.
    Type: Application
    Filed: March 12, 2015
    Publication date: July 2, 2015
    Inventors: Leland W.K. Chung, Lucjan STREKOWSKI, Chunmeng SHI, Maged HENARY, Gabor PATONAY, James J. KRUTAK, Xiaojian YANG, Guodong ZHU, Ruoxiang WANG, Haiyen E. ZHAU
  • Publication number: 20130263297
    Abstract: The present invention relates to metastases. More specifically, the invention relates to compositions and methods for the inhibition of metastases of cancer cells, such as prostate cancer cells, to bones and soft tissue. The present invention also relates to the treatment of cancer, including but not limited to prostate cancer. Also provided are animal models for studying cancer metastasis; particularly, prostate cancer metastasis. Further provided are compositions, processes and systems to prognosticate cancer.
    Type: Application
    Filed: May 7, 2013
    Publication date: October 3, 2013
    Inventors: Gina C.Y. Chu, Leland W.K. Chung, Haiyen E. Zhau, Ruoxiang Wang
  • Publication number: 20130101513
    Abstract: The present invention describes methods of identifying, detecting, imaging, isolating and locating cancer cells in a subject. The method invokes the use of near-infrared (NIR) organic carbocyanine dyes, particularly, near infrared heptamethine cyanine dyes and the detection of the fluorescence of these NIR dyes. The uptake of these dyes by cancer cells and not by normal cells, as well as their high intensity, among other things, allow for the detection of cancerous cells in a subject and facilitate their subsequent isolation. Further, detection of many tumor types and tumor cell populations under cell culture and in vivo conditions are described.
    Type: Application
    Filed: March 16, 2011
    Publication date: April 25, 2013
    Inventors: Xiaojian Yang, Haiyen E. Zhau, Ruoxiang Wang, Leland W.K. Chung
  • Publication number: 20130039854
    Abstract: A mechanism of monoamine oxidases (MAOs) driven epithelium-to-mesenchymal transition (EMT) is disclosed. Also disclosed are methods for treating cancer by inhibiting or suppressing MAOs in cancer cells. Novel MAOs inhibitors, such as small molecules, siRNA, shRNA, antisense oligonucleotides, aptamers, decoys, and pharmaceutical compositions useful for treating cancer by disrupting the workings of MAOs are provided. In particular, a class of conjugates formed by covalently conjugating near infrared dye 783, IR-780, and MHI-148 to a MAO inhibitor, such as clorgyline, with and without encapsulation it in a nanoparticle is provided. Other aspects of the invention include methods for forming the nano-conjugates, method for monitoring treatment progress in a cancer patient by monitoring the changes in MAO activity, methods for screening patients who are at risk of cancer or differentiating different forms of cancer by assaying the level and location of MAO activity.
    Type: Application
    Filed: July 26, 2012
    Publication date: February 14, 2013
    Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Jean C. SHIH, Leland CHUNG, Haiyen E. ZHAU, Boyang Jason WU, Bogdan Z. OLENYUK
  • Publication number: 20110262354
    Abstract: This invention relates generally to cyanine-containing compounds; pharmaceutical compositions comprising cyanine-containing compounds; and methods of using cyanine-containing compounds for cancer cell imaging, cancer cell growth inhibition, and detecting cancer cells, for example. Compounds of the invention are preferentially taken up by cancer cells as compared to normal cells. This allows many uses in the cancer treatment, diagnosis, tracking and imaging fields.
    Type: Application
    Filed: July 10, 2008
    Publication date: October 27, 2011
    Inventors: Leland W. K. Chung, Ruoxiang Wang, Haiyen E. Zhau, Lucjan Strekowski, Maged Henary, Gabor Patonay, James J. Krutak, Xiaojian Yang, Guodong Zhu
  • Publication number: 20110142848
    Abstract: A method for treating cancer includes treating a subject with an agent against beta-2-microglobulin; and treating the subject with radiation or a cancer therapeutic agent. The agent against beta-2-microglobulin includes anti-b2-M antibodies and miRNAs.
    Type: Application
    Filed: August 7, 2009
    Publication date: June 16, 2011
    Inventors: Leland W.K. Chung, Sajni Josson, Wen-Chin Huang, Haiyen E. Zhau
  • Publication number: 20090028832
    Abstract: The present invention relates to a method of treating a human patient having one or more tumor cells. In one embodiment, the method comprises the step of implanting at or around the site of one or more tumor cells in the patient a cell population comprising one or more prostate cancer cells characterized in that the one or more prostate cancer cells have the propensity of metastasizing to skeleton and soft tissues which represent one or more lethal phenotypes of human prostate cancer.
    Type: Application
    Filed: August 10, 2007
    Publication date: January 29, 2009
    Inventors: Leland F. Chung, Haiyen E. Zhau
  • Patent number: 5874305
    Abstract: A new prostate cancer cell line is a continuous line of androgen-repressed metastatic prostate cancer cells. Androgen-repressed prostate cancer cells are linked with aggressive, malignant prostate cancer, in the identification and establishment of androgen-repressed prostate cancer cell lines, which are stable and continuous, allows the examination of therapeutic agents therefor, as well as identification of biological markers for the same.
    Type: Grant
    Filed: January 30, 1996
    Date of Patent: February 23, 1999
    Assignee: University of Virginia Patent Foundation
    Inventors: Leland W.K. Chung, Haiyen E. Zhau, Shi-ming Chang
  • Patent number: 5359031
    Abstract: The present invention involves a method for detecting bladder cancer in a subject. The method preferably comprises first collecting a urine sample from the subject. The presence of a proteinaceous substance having a molecular weight of about 180 kDa according to its relative electrophoretic migration rate through detergent-containing polyacrylamide gel is then measured. This substance reversibly binds concanavalin A and is complexed with gamma globulin while in the urine. The gamma globulin complex binds to Staphlococcal protein A. Said proteinaceous substance, when present in detectable amount, is an indicator of bladder cancer.
    Type: Grant
    Filed: April 28, 1992
    Date of Patent: October 25, 1994
    Assignee: Board of Regents, The University of Texas System
    Inventors: Haiyen E. Zhau, Richard J. Babaian
  • Patent number: 5221612
    Abstract: The present invention involves a method for detecting bladder cancer in a subject. The method preferably comprises first collecting a urine sample from the subject. The presence of a proteinaceous substance having a molecular weight of about 180 kDa according to its relative electrophoretic migration rate through detergent-containing polyacrylamide gel is then measured. This substance reversibly binds concanavalin A and is complexed with gamma globulin while in the urine. The gamma globulin complex binds to Staphlococcal protein A. Said proteinaceous substance, when present in detectable amount, is an indicator of bladder cancer.The method of the present invention for diagnosing bladder cancer in a subject may also be described as comprising detection in a urine sample from said subject of a proteinaceous substance having a molecular weight of about 180 kDa and being unreactive with antibodies specifically binding to carcinoembryonic antigen or epidermal growth factor receptor.
    Type: Grant
    Filed: March 3, 1989
    Date of Patent: June 22, 1993
    Assignee: Board of Regents, The University of Texas System
    Inventors: Haiyen E. Zhau, Richard J. Babaian